Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152


Type-specific cell line models for type-specific ovarian cancer research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4. PLoS One. 2013;8(9). doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a.


TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.


Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Kurman RJ, Shih IeM.

Hum Pathol. 2011 Jul;42(7):918-31. doi: 10.1016/j.humpath.2011.03.003. Review.


Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.


Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.


Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.

Ramalingam P.

Oncology (Williston Park). 2016 Feb;30(2):166-76. Review.


TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK.

Int J Oncol. 2015 Feb;46(2):607-18. doi: 10.3892/ijo.2014.2747. Epub 2014 Nov 11.


Histotype-specific copy-number alterations in ovarian cancer.

Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, Wong MK, Konishi I, Thiery JP, Goh L.

BMC Med Genomics. 2012 Oct 18;5:47. doi: 10.1186/1755-8794-5-47.


Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.

Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.

Cancer Lett. 2015 Jul 1;362(2):218-28. doi: 10.1016/j.canlet.2015.03.040. Epub 2015 Apr 8.


[Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].

Devouassoux-Shisheboran M, Genestie C, Ray-Coquard I.

Bull Cancer. 2016 Mar;103(3):252-8. doi: 10.1016/j.bulcan.2015.12.005. Epub 2016 Feb 4. Review. French.


Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

McCluggage WG.

Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Review.


Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.

Ab Mutalib NS, Syafruddin SE, Md Zain RR, Mohd Dali AZ, Mohd Yunos RI, Saidin S, Jamal R, Mokhtar NM.

BMC Res Notes. 2014 Nov 17;7:805. doi: 10.1186/1756-0500-7-805.


Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.

J Pathol. 2010 Feb;220(3):392-400. doi: 10.1002/path.2659.


Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.

Xiao X, Yang G, Bai P, Gui S, Nyuyen TM, Mercado-Uribe I, Yang M, Zou J, Li Q, Xiao J, Chang B, Liu G, Wang H, Liu J.

BMC Cancer. 2016 Aug 2;16:582. doi: 10.1186/s12885-016-2617-2.


Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.

Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Review.


Molecular pathology of epithelial ovarian cancer.

Christie M, Oehler MK.

J Br Menopause Soc. 2006 Jun;12(2):57-63. Review.


Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.

J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.


Low-grade serous ovarian cancer: A review.

Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA.

Gynecol Oncol. 2016 Nov;143(2):433-438. doi: 10.1016/j.ygyno.2016.08.320. Epub 2016 Aug 28. Review.


Supplemental Content

Support Center